Related references
Note: Only part of the references are listed.Clinical Implications of an Acute Dip in eGFR after SGLT2 Inhibitor Initiation
Hiddo J. L. Heerspink et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)
Chronic Kidney Disease Testing Among Primary Care Patients With Type 2 Diabetes Across 24 US Health Care Organizations
Nikita Stempniewicz et al.
DIABETES CARE (2021)
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
Francesco Cosentino et al.
EUROPEAN HEART JOURNAL (2020)
Different Strategies to Execute Multi-Database Studies for Medicines Surveillance in Real-World Setting: A Reflection on the European Model
Rona Gini et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials
David Z. Cherney et al.
DIABETOLOGIA (2020)
Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study
Bjorn Pasternak et al.
BMJ-BRITISH MEDICAL JOURNAL (2020)
Nephroprotection by SGLT2 Inhibition: Back to the Future?
Luca De Nicola et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Dapagliflozin in Patients with Chronic Kidney Disease
Hiddo J. L. Heerspink et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study
Gian Paolo Fadini et al.
DIABETES OBESITY & METABOLISM (2019)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Canagliflozin for Japanese patients with chronic heart failure and type II diabetes
Akira Sezai et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study)
Sho Kinguchi et al.
CARDIOVASCULAR DIABETOLOGY (2019)
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
Brendan L. Neuen et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial
Ofri Mosenzon et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial
Lindsay E. Clegg et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Renal and Glucose-Lowering Effects of Empagliflozin and Dapagliflozin in Different Chronic Kidney Disease Stages
Yi-Hsuan Lin et al.
FRONTIERS IN ENDOCRINOLOGY (2019)
Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study
Hiddo J L Heerspink et al.
Lancet Diabetes & Endocrinology (2019)
Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study
Gian Paolo Fadini et al.
DIABETES OBESITY & METABOLISM (2018)
Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs The CVD-REAL 2 Study
Mikhail Kosiborod et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
Vlado Perkovic et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World)
Jacob A. Udell et al.
CIRCULATION (2018)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Diabetic Kidney Disease: A Report From an ADA Consensus Conference
Katherine R. Tuttle et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2014)
Modification of Diet in Renal Disease (MDRD) Study and CKD Epidemiology Collaboration (CKD-EPI) Equations for Taiwanese Adults
Ling-I Chen et al.
PLOS ONE (2014)
Matching Methods for Causal Inference: A Review and a Look Forward
Elizabeth A. Stuart
STATISTICAL SCIENCE (2010)
Share Paper
